Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127261691 | 12726169 | 1 | I | 20160901 | 20160908 | 20160908 | EXP | US-MYLANLABS-2016M1037935 | MYLAN | PENG TJ, PATCHETT ND, BERNARD SA. TAKOTSUBO CARDIOMYOPATHY AND CATATONIA IN THE SETTING OF BENZODIAZEPINE WITHDRAWAL. CASE-REP-CARDIOL 2016. | 0.00 | Y | 0.00000 | 20160908 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127261691 | 12726169 | 1 | PS | LORAZEPAM. | LORAZEPAM | 1 | Unknown | 2 MG, QD | 77657 | 2 | MG | QD | |||||||
| 127261691 | 12726169 | 2 | C | BUPRENORPHINE W/NALOXONE | BUPRENORPHINE HYDROCHLORIDENALOXONE HYDROCHLORIDE | 1 | Oral | U | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127261691 | 12726169 | 1 | Anxiety |
| 127261691 | 12726169 | 2 | Drug abuse |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127261691 | 12726169 | OT |
| 127261691 | 12726169 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127261691 | 12726169 | Catatonia | |
| 127261691 | 12726169 | Stress cardiomyopathy | |
| 127261691 | 12726169 | Withdrawal syndrome |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |